The latest orphan drug exemptions may not be warranted, analysis finds | STAT
statnews.com · 237 words · saved by 1 readers
A new analysis questions the wisdom of a controversial provision in federal law that exempts so-called orphan drugs from Medicare pricing negotiations.
By Ed Silverman Aug. 4, 2026 Pharmalot Columnist, Senior Writer Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. A controversial provision in the One Big Beautiful Bill Act, which exempts more so-called orphan drugs from Medicare pricing negotiations in order to encourage further development, may not warrant that protection, according to a new analysis. At issue is a portion of the Inflation…
saved by
related reading
- Marginal REVOLUTIONmarginalrevolution.com
- Inside the Mafia of Pharma Pricing - BIG by Matt Stollerthebignewsletter.com
- Why fixing the IRA matters to all of us - RApportrapport.bio
- Rare Diseases at FDA | FDAfda.gov
- Why kid-friendly medications can be expensive for parentspbs.org
- How PBMs can use private-labelled drug products as a great escape from anti-steering policies - 46brooklyn Research46brooklyn.com
- Joe Biden Lowered Drug Prices. Does Anyone Care? - The Atlantictheatlantic.com
- Where are all the trillion dollar biotechs?ladanuzhna.xyz
- NIH study suggests people with rare diseases face significantly higher health care costs | National Institutes of Health (NIH)nih.gov
- How Medicaid cuts could lead to loss of coverage for millions | Harvard T.H. Chan School of Public Healthhsph.harvard.edu
- Understanding the No Surprises Actbrookings.edu
- Biotech’s Lost Archive | IFPifp.org